Toki S, Newcomb DC, Printz RL, Cahill KN, Boyd KL, Niswender KD, et al
People taking GLP-1 medications arent just changing their health theyre changing how they spend money, according to two recent studies tracking spending habits of people on weight loss drugs
Their identification of the amino acid sequence of the biologically active GLP-1 hormone laid the groundwork for drugs in the management of type 2 diabetes
In addition, although changes in oxidative stress markers have been reported, direct evidence linking GLP-1RA therapy to constrained redox buffering capacity remains limited
Novo Nordisk (the maker of Wegovy) and Eli Lilly (the maker of Zepbound) have both decreased the price of these weight loss drugs for people who are paying out of pocket or do not have insurance coverage for weight loss drugs